ADDENDUM TO AMENDED AND RESTATED PATENT ACCESS AGREEMENT: REDUCTION OF ROYALTIES WITH RESPECT TO SPL TERRITORYPatent Access Agreement • February 20th, 2009 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS ADDENDUM (“Addendum 1”) is made as February 18, 2009, among (1) Sucampo AG, a corporation organized and existing under the laws of Switzerland and having its principal office at Graben 5, CH-6300 Zug, Switzerland (“SAG”), (2) Sucampo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware, U.S.A. and having its principal office at 4520 East West Highway, 3rd Floor, Bethesda, MD 20814, U.S.A. (and as of December 29, 2008, d/b/a Sucampo Pharma Americas, Inc.) (“SPI”), (3) Sucampo Pharma, Ltd., a corporation organized and existing under the laws of Japan and having its principal office at 2-2-16 Sonezakishinchi, Kita-Ku, Osaka, Japan 530-0002 (“SPL”), and (4) Sucampo Pharma Europe, Ltd., a corporation organized and existing under the laws of the United Kingdom and having its principal office at John Eccles House, Robert Robinson Avenue, Oxford Science Park, Oxford, OX4 4GP U.K. (“SPE”) (each referred to herein as a “party” and collectively
